trending Market Intelligence /marketintelligence/en/news-insights/trending/SBXXOP0CElfYsPdoYFnyOg2 content esgSubNav
In This List

2A Pharma secures technology to develop vaccine treatments

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


2A Pharma secures technology to develop vaccine treatments

Swedish biotech 2A Pharma AB secured a license to use Medigene AG's AAVLP technology to develop vaccine treatments.

The preclinical stage, adeno-associated virus-like particles technology is believed to have the potential to develop vaccines for cancer and infectious diseases.

The technology is unrelated to Medigene's current immunotherapy programs and was a former research project at the company before it focused on T-cell immunotherapy.

Medigene will receive undisclosed milestone payments as well as royalties on sales of future AAVLP products as a result of the agreement.